# Utilization and Lifetime Costs of Formal Care for Alzheimer's Disease Dementia in Sweden.

- **DOI:** [10.1007/s40273-026-01612-5](https://doi.org/10.1007/s40273-026-01612-5)
- **Rating:** Sound (3.6 out of 5)
- **Verdict:** Swedish register linkage yields useful stage-specific care estimates, but the headline lifetime cost rests on an eight-year proxy with sparse long follow-up.
- **Framework version:** v5.9
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-10-08
- **Evaluation page:** https://www.nabu.science/paper/10.1007%2Fs40273-026-01612-5

## Key claims

1. The average lifetime costs of formal care for AD dementia were 2,440,000 SEK compared with 510,000 SEK for matched controls, resulting in a difference of 1,930,000 SEK.
   - Support: Supported
   - Type: Primary finding
   - Basis: an eight-year proxy with sparse long follow-up, restricted matching, and potentially biased control truncation
   - Location: Results, Lifetime Costs of AD Dementia
2. The number of outpatient specialist visits decreased as AD severity increased, while the number of drug prescriptions and social care utilization increased with advancing AD stages.
   - Support: Well-supported
   - Type: Secondary
   - Basis: direct stage-specific register estimates with bootstrapped confidence intervals in Table 3
   - Location: Abstract, Results; Table 3
3. These findings can be generalizable to other Nordic countries, considering their similar healthcare system structures.
   - Support: Tentative
   - Type: Secondary
   - Basis: single-country Swedish data and local care costs do not directly establish Nordic transferability
   - Location: Discussion, implications paragraph

## Strengths

- **Large linked register-based patient cohort** The study links SveDem with national healthcare and social-care registers for 20,366 people diagnosed with AD dementia, enabling resource estimates across medical and municipal care.
  - Dimension: methodological rigour
  - Location: Methods, Study Design and Study Population; Measurements of HCRU
- **Granular utilization across dementia stages** Table 3 reports annual utilization across very mild, mild, moderate, and severe AD dementia, including specialist visits, prescriptions, home care, and institutionalization.
  - Dimension: contribution
  - Location: Results, HCRU and Annual Costs of Formal Care by AD Dementia Stages; Table 3
- **Limitations traced to bias direction** The discussion explains how omitted primary care, finite follow-up, control truncation, and informative censoring could affect the magnitude or direction of the estimates.
  - Dimension: positioning
  - Location: Discussion, limitations paragraph

## Limitations

- **Lifetime estimate is an eight-year proxy** The headline 2.44-million-SEK estimate represents accumulated costs over a maximum of eight years, while median follow-up was 1.88 years and only 1.37% were observed for at least seven years.
  - Dimension: methodological rigour
  - Location: Methods, Statistical Analysis; Results, Lifetime Costs of AD Dementia
- **Comparator difference may be upward biased** Controls were matched only on birth year, sex, and region, and their follow-up was truncated with that of cases. The discussion acknowledges that truncation may overestimate the AD–control cost difference.
  - Dimension: methodological rigour
  - Location: Methods, Study Design and Study Population; Discussion, limitations paragraph
- **Nordic transferability remains unvalidated** The extension to other Nordic countries rests on broadly similar healthcare structures rather than direct cross-country evidence, despite country-specific unit costs and service organization.
  - Dimension: application pathway
  - Location: Table 1; Discussion, implications paragraph

## Reliability checks

Caveats (4 of 4 checks).

- **Results check:** Clean. The reported numbers and statistics are consistent with the stated results.
- **Reporting and transparency:** Noted. The conversion of annual daytime-activity unit costs to utilization measured in days is not explained, and the malformed five-year follow-up count is consistent with 2,106 participants; neither establishes a changed cost result.
  - Ethics approval: declared · Data availability: not stated · Code availability: not stated
- **Reference integrity:** Clean
  - 32 references in manuscript
  - 27 of 27 checkable references found in an index
  - 5 are books, websites or datasets — counted, but not index-checkable
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-10-17
